97164 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons Interferons
CLEC9A BINDING AGENTS
#2DOWNREGULATING INOS TO INCREASE CAR-T KILLING
#3METHODS AND COMPOSITIONS INVOLVING CHIMERIC BINDING POLYPEPTIDES
#4CD8 BINDING AGENTS
#5METHODS OF TREATING THE EFFECTS OF CYTOKINE STORMS
#6METHOD OF ADMINISTRATION OF AN ANTI-IFN-ALPHA/-OMEGA ANTIBODY
#7USE OF EMAPALUMAB FOR TREATMENT
#8INTERFERON GAMMA VARIANTS AND ANTIGEN BINDING MOLECULES COMPRISING THESE
#9METHOD OF TREATING VITILIGO WITH INTERFERON-GAMMA ANTIBODY
#10DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#11ENHANCING NON-VIRAL DNA DELIVERY AND EXPRESSION
#12RETROVIRAL-LIKE PARTICLE-REDUCED CHINESE HAMSTER OVARY PRODUCTION CELL LINES
#13METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
#14SINGLE DOMAIN ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS
#15PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS
#16COMPOSITIONS OF PROTEIN COMPLEXES AND METHODS OF USE THEREOF
#17TARGETED INTERFERON ALPHA FUSION PROTEINS AND METHODS OF USE
#18COMPOSITIONS FOR INTERFERON BLOCKADE AND METHODS OF USING SAME
#19CHIMERIC ANTIGEN RECEPTORS AND MODIFIED CELLS COMPRISING THE SAME
#20INTERFERON BETA ANTIBODIES AND USES THEREOF
#21CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY
#22COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY
#23SINGLE DOMAIN ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS
#24Interferon Prodrugs and Methods of Making and Using the Same
#25Compositions of protein complexes and methods of use thereof
#26METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE
#27Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
#28IN VIVO IMMUNOIMAGING OF INTERFERON-GAMMA
#29Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
#30PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAIN
#31Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
#32MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF
#33METHODS OF TREATMENT USING ILT7 BINDING PROTEINS
#34Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain
#35METHODS AND COMPOSITIONS INVOLVING CHIMERIC BINDING POLYPEPTIDES
#36Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
#37ARTIFICIAL ANTIGEN PRESENTING MOLECULES AND THEIR USES
#38METHODS OF HIGH-THROUGHPUT IDENTIFICATION OF T CELL EPITOPES BY CAPTURING CYTOKINES ON THE SURFACE OF ANTIGEN-PRESENTING CELLS
#39CLEC9A BINDING AGENTS
#40TREATMENT METHODS FOR EYE DISORDERS
#41METHODS AND COMPOSITIONS FOR TARGETING TGF-ß SIGNALING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
#42MEDICAMENT AND METHOD FOR TREATING INFECTIOUS DISEASES
#43METHODS FOR REDUCING TOXICITY OF A CHEMOTHERAPEUTIC DRUG
#44SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC FUSION PROTEIN
#45CD8 BINDING AGENTS
#46Anti-TNF/IFN scFv-Fc bispecific antibody and uses thereof
#47COMBINATION IMMUNOTHERAPY
#48Antibody therapies and methods for treating coronavirus infection
#49TYPE 1 INTERFERON NEUTRALIZING FC-FUSION PROTEIN AND USE THEREOF
#50REACTIVE PEPTIDE LABELING
#51Compositions of protein complexes and methods of use thereof
#52Protein signatures for distinguishing between bacterial and viral infections
#53DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#54Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART
#55CANCER TARGETS AND USES THEREOF
#56MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF
#57Human anti-IFN-α antibodies
#58ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF
#59ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF
#60Interferon beta antibodies and uses thereof
#61BISPECIFIC SIGNALING AGENTS AND USES THEREOF
#62Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
#63Anti-interferon gamma antibodies and uses thereof
#64GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
#65Delivering biological drugs to tissues
#66Compositions for interferon blockade and methods of using same
#67COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY
#68Method of administration of an anti-IFN-α/-ω antibody
#69A NOVEL INTERFERON-(lambda)4 (IFNL-4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF
#70Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
#71Methods and pharmaceutical compositions for modulating monocytopoiesis
#72In vivo immunoimaging of interferon-gamma
#73Compositions and methods for treating alzheimer's disease
#74METHODS OF PURIFYING BISPECIFIC ANTIBODIES
#75Reactive peptide labeling
#76PEPTIDES FOR USE IN TREATMENT AND DIAGNOSIS OF TYPE 1 DIABETES
#77Peptide for toll-like receptor (TLR) inhibition and pharmaceutical composition comprising same
#78Anti-tumor T cells and their preparation using IL-6
#79Bispecific signaling agents and uses thereof
#80Anti-cancer T cells and their preparation using coenzyme A
#81Interferon alpha and omega antibody antagonists
#82Clec9A binding agents
#83Safe and effective method of treating lupus with anti-IL12/IL23 antibody
#84Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein
#85CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy
#86PNEUMOCOCCAL INHIBITORY FACTOR COMPOSITIONS AND METHODS OF USE THEREOF
#87Glucocorticoid receptor agonist and immunoconjugates thereof
#88Interferon Alpha and Omega Antibody Antagonists
#89Protein signatures for distinguishing between bacterial and viral infections
#90Interferon alpha and omega antibody antagonists
#91Methods for reducing toxicity of a chemotherapeutic drug
#92CD8 binding agents
#93Human anti-IFN-α antibodies
#94METHODS OF PURIFYING ANTIBODIES
#95Tandemly repeated antibody-binding protein and its applications
#96Methods for increasing levels of interferon activity with an interferon lambda 3 polypeptide
#97METHOD FOR THE TREATMENT OF PAIN AND OSTEOARTHRITIS WITH C-FMS ANTAGONISTS
#98Combination immunotherapy
#99CANCER TARGETS AND USES THEREOF
#100Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
#101Methods for the generation of multispecific and multivalent antibodies
#102METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA THERAPY
#103Methods of treatment using an interferon gamma inhibitor
#104Interferon alpha and omega antibody antagonists
#105INTERFERON ALPHA ANTIBODIES AND THEIR USES
#106Interferon beta antibodies and uses thereof
#107ANTI-INTERFERON GAMMA ANTIBODIES AND METHODS OF USE THEREOF
#108Production of proteins in labyrinthulomycetes
#109Interferon-λ4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof
#110Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
#111INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
#112COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
#113METHOD AND COMPOSITION FOR THE TREATMENT OF DISEASES CAUSED BY OR ASSOCIATED WITH HIV
#114Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
#115Human anti-IFN-α antibodies
#116CANCER TARGETS AND USES THEREOF
#117Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
#118TYPE I INTERFERON MIMETICS AS THERAPEUTICS FOR CANCER, VIRAL INFECTIONS, AND OTHER DISEASES
#119Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#120Methods of purifying bispecific antibodies
#121METHOD OF TREATING A PATHOLOGICAL SYNDROME
#122Method for increasing interferon activity in an individual
#123MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) PROMOTER POLYMORPHISM IN INFLAMMATORY DISEASE
#124Method for treatment of osteoarthritis with C-Fms antagonists
#125Construction of diverse synthetic peptide and polypeptide libraries
#126METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR
#127Methods and arrays for use in the same
#128Type I Interferon Diagnostic
#129Interferon α and ω antibody antagonists
#130ANTIBODY FORMULATION
#131ANTI-INTERFERON ALPHA MONOCLONAL ANTIBODIES AND METHODS OF USE
#132ANTIBODIES WITH DECREASED DEAMIDATION PROFILES
#133INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
#134Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
#135Interferon-λ4 (IFNL4) protein, related nucleic acid molecules, and uses thereof
#136INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
#137METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT
#138COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES
#139COMBINATION PHARMACEUTICAL COMPOSITION AND METHODS OF TREATING AND PREVENTING THE INFECTIOUS DISEASES
#140Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
#141Interferon alpha and omega antibody antagonists
#142Use of M-CSF antibodies in the treatment of osteoarthritis or pain
#143Methods for preparing interferon alpha antibodies
#144Anti-interferon gamma antibodies and methods of use thereof
#145Methods for the generation of multispecific and multivalent antibodies
#146Anti-interferon alpha monoclonal antibodies and methods for use
#147Methods of treating multiple sclerosis
#148Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same
#149Methods of treating multiple sclerosis
#150Method of treating hypertension disorder and a pharmaceutical agent
#151COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES
#152Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
#153Methods of purifying antibodies
#154ANTI-INTERFERON-ALPHA ANTIBODIES
#155Method of treating a pathological syndrome and a pharmaceutical agent
#156Nucleic acids encoding interferon alpha antibodies
#157Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#158Humanized antibodies against human interferon-alpha
#159ANTI-INTERFERON-ALPHA ANTIBODIES
#160Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
#161Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier
#162IFN-GAMMA INHIBITORS IN THE TREATMENT OF MOTONEURON DISEASES
#163Methods for treating IFN-γ mediated diseases using human anti-IFN-γ neutralizing antibodies as selective IFN-gamma pathway inhibitors
#164TYPE 1 INTEFERON DIAGNOSTIC
#165STABILIZED SINGLE DOMAIN ANTIBODIES
#166Anti-interferon-α antibodies
#167Pharmaceutical compositions comprising activated-potentiated antibodies to interferon-gamma and S100 protein
#168SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#169Construction of diverse synthetic peptide and polypeptide libraries
#170Humanized antibodies against human interferon-alpha
#171Compositions and methods to treat and control tumors
#172Methods for the generation of multispecific and multivalent antibodies
#173Design and construction of diverse synthetic peptide and polypeptide libraries
#174Interferon-lambda 1 polypeptides
#175PHARMACEUTICAL AGENT
#176Compositions of F(ab′)antibody fragments
#177Method of treating viral diseases
#178Anti-inteferon alpha monoclonal antibodies and methods for use
#179Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
#180Stable aqueous pharmaceutical formulations of daclizumab antibodies
#181Interferon alpha antibodies and their uses
#182INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
#183ANTI-INTERFERON-ALPHA ANTIBODIES
#184ANTIBODY FORMULATION
#185Humanized antibodies against human interferon-alpha
#186Anti-interferon-α antibodies
#187Cell, method and kit for conducting an assay for neutralizing antibodies
#188SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR
#189SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#190METHOD OF ADMINISTERING THERAPEUTIC POLYPEPTIDES, AND POLYPEPTIDES THEREFOR
#191STABILIZED SINGLE DOMAIN ANTIBODIES
#192IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES
#193ANTIBODIES WITH DECREASED DEAMIDATION PROFILES
#194SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR
#195ANTIBODY PURIFICATION PROCESS
#196Blockage of interferon-gamma for prevention of polymicrobial synergy
#197Monoclonal antibodies specific for human interferon-alpha subtype alpha 8
#198Method for administering homeopathically potentiated antibodies against mediator of inflammation
#199METHODS FOR MODULATING IMMUNE RESPONSES TO AAV GENE THERAPY VECTORS
#200STABLE LIQUID PHARMACEUTICAL FORMULATION OF IGG ANTIBODIES
#201Nucleic acid molecules that encode human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
#202Avian cytokines and genetic sequences encoding same
#203SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#204METHODS OF TREATING SCLERODERMA
#205Method of treating disorders of the cardiovascular system and a pharmaceutical agent
#206Method of treating a pathological syndrome and a pharmaceutical agent
#207ANTIBODY FORMULATION
#208Method of treating a disorder or condition of viral etiology
#209Method for administering homeopathically potentized antibody
#210Anti-Interferon Gamma Antibodies and Methods of Use Thereof
#211METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
#212INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
#213POLYPEPTIDE CONSTRUCTS FOR SUBLINGUAL ADMINISTRATION
#214Polypeptide constructs including VHH directed against EGFR for intracellular delivery
#215SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREFOR
#216POLYPEPTIDE CONSTRUCTS FOR TOPICAL ADMINISTRATION
#217POLYPEPTIDE CONSTRUCTS FOR RECTAL AND/OR VAGINAL ADMINISTRATION
#218Interferon alpha antibodies and their uses
#219POLYPEPTIDE CONSTRUCTS FOR NASAL ADMINISTRATION
#220Medicament and a method of treating a pathological syndrome
#221Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays
#222Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
#223Stabilized single domain antibodies
#224IFN-λ polypeptides and compositions
#225Anti-interferon alpha monoclonal antibodies and methods for use
#226Interferon-beta polymer conjugates
#227Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
#228Pharmaceutical composition of F(ab′)antibody fragments and a process for the preparation thereof
#229Construction of diverse synthetic peptide and polypeptide libraries
#230Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#231Methods and uses of antibodies in the purification of interferon
#232Flame-retardant resin composition
#233Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
#234Prevention and treatment of sepsis
#235Anti-interferon alpha monoclonal antibodies and methods for use
#236Humanized immunoglobulins
#237Method of treating a pathological syndrome and a pharmaceutical agent
#238Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
#239Method of treating a pathological syndrome and a pharmaceutical agent
#240Method of treating a pathological syndrome and a pharmaceutical agent
#241Method of promoting the healing of a chronic wound
#242Method of treating a pathological syndrome and a pharmaceutical agent
#243Method of treating a pathological syndrome and a pharmaceutical agent
#244Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#245Method of treating a pathological syndrome and a pharmaceutical agent
#246Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
#247High-yield method for the production of human antibodies blocking the biological activity of a human cytokine
#248Stabilized single domain antibodies
#249Interferon antagonists useful for the treatment of interferon related diseases
#250Treatment of Inflammatory Bowel Disease with IFN-Gamma Inhibitors
#251Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#252Compositions and methods for treating hyperimmune response in the eye
#253Anti-interferon-α antibodies
#254Anti-interferon-α antibodies
#255Compositions and methods to treat and control tumors by loading antigen presenting cells
#256Recombinant DNA-molecule complex for the expression of anti-human-interferon-gamma chimeric antibodies or antibody fragments
#257Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of ifn-gamma activity
#258TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH IFN-GAMMA INHIBITORS
#259Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
#260Anti-interferon alpha antibodies
#261Antagonist of Th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
#262Anti-interferon gamma antibodies and methods of use thereof
#263Administration of anti-cytokine f(ab')2 antibody fragments
#264Treatment of herpes
#265Treatment of AIDS
#266Treatment of schizophrenia
#267Treatment of autism
#268Treatment of autism
#269Treatment of inflammatory skin diseases
#270Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
#271Method for obtaining single chain antibodies to human interferon α2b
#272Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
#273Single domain antibodies directed against interferron-gamma and uses therefor
#274Media and method for treating pathological syndrome
#275Treatment of acne
#276Treatment of autism
#277Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
#278Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-gamma
#279Methods of treating NFAT-related disorders
#280Compositions and methods for treating hyperimmune response in the eye
#281Treatment of autoimmune diseases, including AIDS
#282Pharmaceutical composition containing inhibitors of interferon-γ
#283Treatment of diabetic retinopathy
#284Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
#285Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
#286Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
#287Treatment of Crohn's disease or psoriasis using anti-interferon gamma antibodies
#288Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
#289Methods of treatment of neurological diseases by interferon antagonists
#290Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
#291Peptides for use in treatment and diagnosis of type 1 diabetes